Exelixis (EXEL) : The money flow is calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades, which was negative (5.22 million) in Exelixis (EXEL). On Tuesday, The value of composite uptick trades was $4.72 million, whereas, the value of composite downtick trades was $9.94 million and the ratio between the two was 0.48, indicating selling on strength. Traders involved in block trades booked profits in their holdings as seen in the transactions on downticks valued at $5.31 million. The negative money flow of ($5.31 million) shows selling on strength. Exelixis (EXEL) gained $0.06 intraday at $11.04 and registrered 0.55% for the week.
Also, Stifel Nicolaus maintains its view on Exelixis (NASDAQ:EXEL) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Stifel Nicolaus raises the price target from $10 per share to $12 per share on Exelixis . The rating by the firm was issued on August 4, 2016.
Exelixis, Inc. has dropped 4.91% in the last five trading days, however, the shares have posted positive gains of 19.09% in the last 4 weeks. Exelixis, Inc. is up 70.37% in the last 3-month period. Year-to-Date the stock performance stands at 95.74%.
Exelixis (NASDAQ:EXEL): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $10.96 and $10.90 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $11.10. The buying momentum continued till the end and the stock did not give up its gains. It closed at $11.04, notching a gain of 0.55% for the day. The total traded volume was 3,608,800 . The stock had closed at $10.98 on the previous day.
In a related news,The officer (Pres Prod Dev & Med Aff & CMO) of Exelixis, Inc., Schwab Gisela sold 42,338 shares at $11 on August 4, 2016. The Insider selling transaction had a total value worth of $465,718. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).